| Identification | More | [Name]
Etamsylate | [CAS]
2624-44-4 | [Synonyms]
ETAMSYLATE
ETHAMSYLATE
1-hydroxy-4-oxo-2,5-cyclohexadiene-1-sulfonicacidcompd.withdiethylamine
2,5-dihydroxy-benzenesulfonicacicompd.withdiethylamine
2,5-dihydroxy-benzenesulfonicacicompd.withn-ethylethanamine(1:1)
2,5-dihydroxybenzenesulfonicacidcompd.withn-ethylethanamine
2,5-DihydroxybenzenesulfonicacidcompdwithN-ethylethanamine
aglumin
altodor
ciclonamina
cyclonamine
dicynene
dicynone
diethylammonium2,5-dihydroxybenzenesulfonate
diethylammoniumcyclohexadien-4-ol-1-one-4-sulfonate
diidroxi-1,4-benzenesulfonato-3-di-etilammonium
e141
eselin
md141
diethylammonium 2,5-dihydroxybenzenesulphonate | [EINECS(EC#)]
220-090-7 | [Molecular Formula]
C10H17NO5S | [MDL Number]
MFCD00867499 | [Molecular Weight]
263.31 | [MOL File]
2624-44-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
125° | [density ]
1.3441 (rough estimate) | [refractive index ]
1.5060 (estimate) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Very soluble in water, freely soluble in methanol, soluble in anhydrous ethanol, practically insoluble in methylene chloride. | [form ]
neat | [color ]
White to Pale Red | [Merck ]
14,3722 | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3 | [InChIKey]
HBGOLJKPSFNJSD-UHFFFAOYSA-N | [SMILES]
C1(S(=O)(=O)O)=CC(=CC=C1O)O.N(CC)CC | [CAS DataBase Reference]
2624-44-4(CAS DataBase Reference) | [EPA Substance Registry System]
2624-44-4(EPA Substance) |
| Safety Data | Back Directory | [RTECS ]
DB6145000 | [HS Code ]
2921.19.6190 | [HazardClass ]
IRRITANT | [Toxicity]
LD50 i.v. in mice, rats: 800, 1350 mg/kg (Esteve) |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Haemostatic / Anti Coagulant | [Uses]
Hemostatic;prostaglandin synthesis inhibitor | [Definition]
ChEBI: Etamsylate is a sulfonic acid derivative and an organosulfur compound. | [Mechanism of action]
Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
| [Clinical Use]
Short-term treatment of blood loss in menorrhagiaProphylaxis of surgical bleeding (unlicensed) | [Side effects]
Significant: Hypotension (parenteral). Rarely, severe hypersensitivity reaction, including anaphylaxis.
Blood and lymphatic system disorders: Parenteral: Rarely, neutropenia, agranulocytosis, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort.
General disorders and administration site conditions: Asthenia (parenteral). Rarely, fever.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Rarely, thromboembolism (parenteral).
| [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Etamsylate is excreted unchanged, mainly in the urine. |
|
|